Jeffrey Low, MD

Jeffrey Low, MD is a Partner at Averin where he invests at the intersection of life sciences, healthcare, and technology. He works with teams advancing therapeutics, care delivery, and the software infrastructure shaping the future of healthcare and life sciences. He also invests as a Scout Partner with Sequoia Capital in early-stage founders applying AI to life sciences and healthcare.

Previously, Jeffrey invested at Andreessen Horowitz (a16z) in therapeutics, AI drug discovery, life sciences technology, and digital health, and was named to Forbes 30 Under 30 in Venture Capital. He later led the life sciences and healthcare technology strategy at Novo Holdings.

Jeffrey earned his MD from Yale School of Medicine, MBA from Harvard Business School, and AB in Molecular and Cellular Biology from Harvard. He is a fourth-generation San Franciscan, avid squash player, and stays engaged with the broader ecosystem by serving as co-chair of Harvard’s regional alumni admissions committee for the San Francisco Bay Area Peninsula and as Program Advisor to the HBS MS/MBA Biotechnology Life Sciences program.